Skip to content

Study · Not a test of the peptide alone · 1996

2 results

The use of the short tetracosactrin test for the investigation of suspected pituitary hypofunction.

Wang TW, Wong MS, Smith JF, Howlett TA

Annals of clinical biochemistry1 Mar 1996Cited by 12 (Europe PMC)

PMID8729718 (opens in a new tab)DOI10.1177/000456329603300203 (opens in a new tab)PepBankPUB-08729718
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

  1. 01HumanNot a test of Cosyntropin aloneNon-randomized trialOther

    In suspected pituitary hypofunction, cortisol responses did not differ significantly between intramuscular and intravenous tetracosactrin.

    In plain wordsIn suspected pituitary hypofunction, cortisol responses did not differ significantly between intramuscular and intravenous tetracosactrin.

    Peptide
    Cosyntropin
    Outcome
    No significant changeCortisol response by administration route
    Study

    n: not reported in source

    Comparator
    Intravenous Synacthen
    Outcome group
    Adrenal Response · Endocrine and hormones

    Source sentences

    Summary
    We found no significant difference between the two routes of administration.
    1 context sentence
    Summary · context
    The present study was done, first, to determine whether there was any difference in cortisol responses when Synacthen was administered intramuscularly compared with intravenously and, secondly, to compare cortisol responses at 30 and 60 min.

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

  2. 02HumanNot a test of Cosyntropin aloneNon-randomized trialOther

    In suspected pituitary hypofunction, cortisol responses after tetracosactrin were higher at 60 min than at 30 min.

    In plain wordsIn suspected pituitary hypofunction, cortisol after tetracosactrin was higher at 60 min than at 30 min.

    Peptide
    Cosyntropin
    Outcome
    IncreaseCortisol response by sampling time
    Study

    n: not reported in source

    Comparator
    30 min after Synacthen
    Outcome group
    Adrenal Response · Endocrine and hormones

    Measurements

    P
    < 0.05
    60 versus 30 min

    Source sentences

    Summary
    However, cortisol responses at 60 min were significantly higher than at 30 min (P < 0.05).
    1 context sentence
    Summary · context
    The present study was done, first, to determine whether there was any difference in cortisol responses when Synacthen was administered intramuscularly compared with intravenously and, secondly, to compare cortisol responses at 30 and 60 min.

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.